POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.448 EUR | -10.40% |
|
-15.15% | -14.34% |
| 04-11 | Poxel: CDC falls below the 10% threshold | CF |
| 02-15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.35M 19.62M | Sales 2022 | 674K 722K 987K | Capitalization | 27.16M 29.09M 39.79M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -24.64M -33.69M | Net income 2022 | -31M -33.2M -45.41M | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.22M 4.4M | Net Debt 2022 | 32.74M 35.06M 47.95M | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
More news
| 1 week | -15.15% | ||
| Current month | -23.94% | ||
| 1 month | -21.13% | ||
| 3 months | -7.34% | ||
| 6 months | -21.95% | ||
| Current year | -14.34% |
1 week
0.44
0.52
1 month
0.440.65
3 years
0.277.11
5 years
0.2713.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 09-03-05 | |
Sebastien Bolze
FOU | Founder | - | 09-03-05 |
| Founder | - | 09-03-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 15-03-11 |
Pascale Boissel
BRD | Director/Board Member | 57 | 15-03-04 |
Thomas Kuhn
FOU | Founder | 50 | 09-03-05 |
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.448 | -10.40% |
| 24-06-27 | 0.5 | -1.57% |
| 24-06-26 | 0.508 | +2.01% |
| 24-06-25 | 0.498 | -0.80% |
| 24-06-24 | 0.502 | -4.92% |
Delayed Quote Börse Stuttgart, June 28, 2024 at 09:36 am
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-08-28
- Q2 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +15.20% | 121B | |
| +19.67% | 113B | |
| +18.95% | 26.02B | |
| -23.86% | 19.39B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B |
- Stock Market
- Equities
- POXEL Stock
- 7PO Stock
